Literature DB >> 19294678

Antibiotic prophylaxis before second-trimester genetic amniocentesis (APGA): a single-centre open randomised controlled trial.

Claudio Giorlandino1, Pietro Cignini, Marco Cini, Cristiana Brizzi, Ornella Carcioppolo, Vincenzo Milite, Claudio Coco, Paolo Gentili, Lucia Mangiafico, Alvaro Mesoraca, Domenico Bizzoco, Ivan Gabrielli, Luisa Mobili.   

Abstract

OBJECTIVE: To compare procedure-related pregnancy loss after second-trimester genetic amniocentesis in women given an antibiotic prophylaxis and controls.
METHODS: Prospective, open randomised controlled single-centre study between January 1999 and December 2005 at Artemisia Fetal Maternal Medical Centre. A follow-up within 4 weeks after the procedure was done.Of 36,347 eligible women, 1424 refused to participate and 34,923 were enrolled and randomised with unequal chance of selection, 21,991 were assigned to treatment group and 12,932 were assigned to the control group, and did not receive any placebo. Oral azithromycin, 500 mg per day, was administered 3 days before amniocentesis. The primary endpoint was the procedure-related pregnancy loss. The secondary endpoint was the rate of preterm premature rupture of membranes.
RESULTS: The rate of abortion related to the amniocentesis was 7/21 219 women (0.03%, 95% CI 0.009-0.057) in the intervention group, and 36/12 529 (0.28%, 0.28-0.30) in controls (p = 0.0019). The rate of preterm premature rupture of membranes was 14/21 219 (0.06%, 0.031-0.101) in the intervention group, and 140/12 529 (1.12%, 0.94-1.30) in the control group (p = 0.001).
CONCLUSIONS: Antibiotic prophylaxis before second-trimester amniocentesis reduced the risk of abortion and of rupture of the membranes. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294678     DOI: 10.1002/pd.2256

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

1.  Position Statement from the Italian College of Fetal Maternal Medicine: Non-invasive prenatal testing (NIPT) by maternal plasma DNA sequencing.

Authors: 
Journal:  J Prenat Med       Date:  2013-04

2.  Six consecutive false positive cases from cell-free fetal DNA testing in a single referring centre.

Authors:  Nella Dugo; Francesco Padula; Luisa Mobili; Cristiana Brizzi; Laura D'Emidio; Pietro Cignini; Alvaro Mesoraca; Domenico Bizzoco; Antonella Cima; Claudio Giorlandino
Journal:  J Prenat Med       Date:  2014 Jan-Mar

3.  MePR: a novel human mesenchymal progenitor model with characteristics of pluripotency.

Authors:  Marco Miceli; Gianluigi Franci; Carmela Dell'Aversana; Francesca Ricciardiello; Francesca Petraglia; Annamaria Carissimo; Lucia Perone; Giuseppe Maria Maruotti; Marco Savarese; Pasquale Martinelli; Massimo Cancemi; Lucia Altucci
Journal:  Stem Cells Dev       Date:  2013-05-24       Impact factor: 3.272

4.  Antimicrobial prophylaxis post-amniocentesis procedures in cattle: A randomized controlled equivalence study.

Authors:  V A Absalón-Medina; R V Sala; R Bond
Journal:  Vet Anim Sci       Date:  2021-12-24

5.  The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis.

Authors:  Nynke R van den Broek; Sarah A White; Mark Goodall; Chikondi Ntonya; Edith Kayira; George Kafulafula; James P Neilson
Journal:  PLoS Med       Date:  2009-12-01       Impact factor: 11.069

6.  The Italian Network for Monitoring Medication Use During Pregnancy (MoM-Net): Experience and Perspectives.

Authors:  Valeria Belleudi; Filomena Fortinguerra; Francesca R Poggi; Serena Perna; Renata Bortolus; Serena Donati; Antonio Clavenna; Anna Locatelli; Marina Davoli; Antonio Addis; Francesco Trotta
Journal:  Front Pharmacol       Date:  2021-06-23       Impact factor: 5.810

7.  Azithromycin prevents pregnancy loss: reducing the level of tumor necrosis factor-alpha and raising the level of interleukin-10 in rats.

Authors:  Ayse Er
Journal:  Mediators Inflamm       Date:  2013-11-24       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.